aTyr Pharma Q1 2026 Earnings Report

aTyr Pharma EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.16
• Beat/Miss: N/A
• One Year Ago EPS: N/A

aTyr Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

aTyr Pharma Announcement Details

• Quarter: Q1 2026
• Date: 5/13/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

aTyr Pharma (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling. Its lead program, ATYR1923, is being investigated for the treatment of pulmonary sarcoidosis, and additional pipeline candidates are advancing in preclinical and early clinical studies for oncology and neuromuscular disorders. aTyr’s platform allows for the rapid screening of protein interactions and the engineering of modulators with potential applications across multiple therapeutic areas.

Founded in 2005, aTyr Pharma completed its initial public offering in 2015 and has since entered into strategic collaborations to accelerate the development and potential commercialization of its product candidates. The company’s research and development activities span North America and Europe, and its leadership team brings together expertise in protein therapeutics, immunology, and clinical development. aTyr continues to leverage its platform to address unmet medical needs and to expand its pipeline through internal discovery and external partnerships.